Referenser
1. Socialstyrelsen, EpC, Folkhälsan i Siffror. www.sos.se/epc/fs
2. Ezzati M, Lopez AD, Rodgers A, Vander HS, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360(9343):1347-1360.
3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J et al. European guidelines on cardiovascular disease prevention in clinical practice.
Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24(17):1601-1610.
4. Melander A, Agren G. Läkemedel har – fortfarande – en mycket låg effektivitet i primär prevention av hjärt–kärlsjukdom. Läkartidningen 2005; 102(10):785.
5. Wilhelmsen L, Perk J. Nya europeiska riktlinjer för kardiovaskulär prevention. Läkartidningen 2004; 101(46): 3677-368.
6. Sagie A, Larson MG, Levy D. The Natural History of Borderline Isolated Systolic Hypertension. N Engl J Med 1993; 329(26):1912-1917.
7. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D‘Agostino RB et al. Residual Lifetime Risk for Developing Hypertension in Middle-aged Women and Men: The Framingham Heart Study. JAMA 2002; 287(8):1003-1010.
8. Prospective Studies Collaboration. Age-specifi c relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349):1903-1913.
9. Wilhelmsen L, Wedel H, Conroy R, Fitzgerald T. Det svenska SCORE-diagrammet för kardiovaskulär risk. Läkartidningen 2004; 101(20):1798-1801.
10. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351(9118):1755-1762.
11. SBU. Måttligt förhöjt blodtryck: En systematisk litteraturöversikt. SBU-rapport 170/1, 451-487. 2004.
12. Jonsson B, Hansson L, Stalhammar NO. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. J Intern Med 2003; 253(4):472-480.
13. Weinehall L, Ohgren B, Persson M, Stegmayr B, Boman K, Hallmans G et al. High remaining risk in poorly treated hypertension: the ‚rule of halves‘ still exists. J Hypertens 2002; 20(10):2081-2088.
14. Bjorklund K, Lind L, Lithell H. Twenty-four hour ambulatory blood pressure in a population of elderly men. J Intern Med 2000; 248(6):501-510.
15. Neaton JD, Grimm RH, Jr., Prineas RJ, Stamler J, Grandits GA, Elmer PJ et al. Treatment of Mild Hypertension Study. Final results. JAMA 1993; 270(6):713-724.
16. Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH, Jr., Neaton JD et al. Comparison of Five Antihypertensive Monotherapies and Placebo for Change in Left Ventricular Mass in Patients Receiving Nutritional-Hygienic Therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91(3):698-706.
17. MacMahon SW, Wilcken DE, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N Engl J Med 1986; 314(6):334-339.
18. Whelton SP, Chin A, Xin X, He J. Effect of Aerobic Exercise on Blood Pressure: A Meta-Analysis of Randomized, Controlled Trials. Ann Intern Med 2002; 136(7):493-503.
19. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med 2004; 116(10): 682-692.
20. Wannamethee SG, Shaper AG, Walker M. Physical Activity and Mortality in Older Men With Diagnosed Coronary Heart Disease. Circulation 2000; 102(12):1358-1363.
21. Pereira MA, Kriska AM, Day RD, Cauley JA, LaPorte RE, Kuller LH. A Randomized Walking Trial in Postmenopausal Women: Effects on Physical Activity and Health 10 Years Later. Arch Intern Med 1998; 158(15):1695-1701.
22. Morris MC, Sacks F, Rosner B. Does fi sh oil lower blood pressure? A meta-analysis of controlled trials. Circulation 1993; 88(2):523-533.
23. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D et al. Effects on Blood Pressure of Reduced Dietary Sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. N Engl J Med 2001; 344(1):3-10.
24. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328(7440):634-640.
25. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr. et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6):
1206-1252.
26. Khan NA, McAlister FA, Lewanczuk RZ, Touyz RM, Padwal R, Rabkin SW et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol 2005; 21(8): 657-672.
27. Hooper L, Bartlett C, Davey Smith G, Ebrahim S. Systematic review of long term effects of advice to reduce dietary salt in adults. BMJ 2002; 325(7365):628.
28. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of Alcohol Reduction on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials. Hypertension 2001; 38(5):1112-1117.
29. Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract 2005; 55(513):305-312.
30. Writing Group of the PREMIER Collaborative Research Group. Effects of Comprehensive Lifestyle Modifi cation on Blood Pressure Control: Main Results of the PREMIER Clinical Trial. JAMA 2003; 289(16):2083-2093.